Correlating phenotype and genotype in the periodic paralyses

@article{Miller2004CorrelatingPA,
  title={Correlating phenotype and genotype in the periodic paralyses},
  author={Timothy M. Miller and Magnus R{\'e}gios Dias da Silva and H A Miller and Hubert Kwiecinski and Jerry R. Mendell and Rabi Tawil and Philip G. McManis and Robert C. Griggs and Corrado Angelini and Serena Servidei and Jack H. Petajan and Marinos C. Dalakas and Laura P. W. Ranum and Y. H. Fu and Louis J. Pt{\'a}{\vc}ek},
  journal={Neurology},
  year={2004},
  volume={63},
  pages={1647 - 1655}
}
BACKGROUND Periodic paralyses and paramyotonia congenita are rare disorders causing disabling weakness and myotonia. [] Key MethodMETHODS The authors have reviewed clinical data in patients with a diagnosis of hypokalemic periodic paralysis (56 kindreds, 71 patients), hyperkalemic periodic paralysis (47 kindreds, 99 patients), and paramyotonia congenita (24 kindreds, 56 patients).

Tables from this paper

The Genotype and Clinical Phenotype of Korean Patients with Familial Hypokalemic Periodic Paralysis

This study presents comprehensive data on the genotype and phenotype of Korean families with HOPP, and detects one novel silent exonic mutation (1950C>T) in the SCN4A gene.

Clinical and Molecular Spectrum of Myotonia and Periodic Paralyses Associated With Mutations in SCN4A in a Large Cohort of Italian Patients

The data suggest that skeletal muscle channelopathies associated with mutations in SCN4A represent a continuum in the clinical spectrum.

Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis.

Recent discoveries in the skeletal muscle channelopathies have increased understanding of the genetics and pathophysiology of these diseases, and studies reporting imaging techniques raise the possibility of improved disease monitoring and better outcome measures for clinical trials.

The primary periodic paralyses: diagnosis, pathogenesis and treatment.

Periodic paralyses (PPs) are rare inherited channelopathies that manifest as abnormal, often potassium (K)-sensitive, muscle membrane excitability leading to episodic flaccid paralysis. Hypokalaemic

Genotype and Phenotype Analysis of Patients With Sporadic Periodic Paralysis

A minority of SPP patients had de novo CACNA1S or SCN4A mutations and may have a variant of FPP, and this form ofSPP usually manifests at a later age, is associated with fewer attacks and lacks apparent triggering factors.

[Hyperkalemic periodic paralysis: a Spanish family with the p.Thr704Met mutation in the SCN4A gene].

The findings of the studied family correlate well with those reported previously in HYPP, although the frequency of the episodes is exceptionally high in the family.

Periodic paralysis.

Hypokalemic periodic paralysis; two different genes responsible for similar clinical manifestations

The cases of 2 patients with HOKPP who both presented with typical clinical manifestations, but with mutations in 2 different genes (CACNA1Sp.Arg528His and SCN4A p.Arg672His) are reported, showing differences in the response to acetazolamide treatment.
...

References

SHOWING 1-10 OF 40 REFERENCES

Genotype-phenotype correlations of DHP receptor alpha 1-subunit gene mutations causing hypokalemic periodic paralysis.

Patients with mutations in the skeletal muscle dihydropyridine receptor alpha 1-subunit that functions as a calcium channel that cause hypoKPP had an earlier age of onset and potassium levels during attacks than patients in whom CACNL1A3 mutations were not identified.

Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families.

It is shown that a founder effect is unlikely to account for the two predominant mutations in hypoPP, and analysis of the clinical characteristics of both groups of families demonstrated that incomplete penetrance is a distinctive feature of the Arg528His mutation.

Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A.

A complete penetrance in men and women, an early age at onset, postcritic myalgias and an increased number and severity of attacks induced by acetazolamide are observed in a large hypoPP family carrying an SCN4A mutation.

Sodium channel mutations in acetazolamide‐responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis

This report summarizes the sodium channel mutation analysis in 25 families with hyperKPP and reports the putative disease-causing mutation in acetazolamide-responsiveMyotonia congenita, a related disease in which myotonia is worsened by potassium but in which episodic weakness does not occur.

A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis.

The first genetic defect in THypoKPP is identified, a mutation in the KCNE3 gene, caused by mutations in the ionic channel genes calcium, sodium and potassium, which is a genetically conditioned complication of thyrotoxicosis.

Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome).

The functional consequences of three novel and seven previously described KCNJ2 mutations using a two-microelectrode voltage-clamp technique and correlated the findings with the clinical phenotype suggest that the substrate for arrhythmia susceptibility in AS is distinct from the other forms of inherited LQT syndrome.

A novel sodium channel mutation in a family with hypokalemic periodic paralysis

The identification of a mutation within the skeletal muscle sodium channel resulting in hypokalemic periodic paralysis represents a novel finding.

Sodium channel mutations in paramyotonia congenita and hyperkalemic periodic paralysis

Five other HYPP and PC families have been ascertained, and previously reported sodium channel mutations have been identified in each, and an additional mutation is reported, a leucine ‐ arginine substirution in the ss segment of domain 4 (L1433R), that results in the PC phenotype.